Figure 6. Omipalisib augments MEK162 effect in combined administration and vice-versa. (A, B, C, left panel) Treatment with increased doses of MEK162 alone or in combination with 1μM omipalisib of C76N, PD1N and C42N cells. (A, B, C, right panel) Increasing doses of omipalisib alone was compared to combination with 1μM MEK162 in C76N, PD1N and C42N cells. Viability was measured by MTT assay after 72 h of treatment. Untreated controls were considered 100% viable. Curves were fitted according to the non-linear regression analysis using Graphpad PRISM.